Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2001 1
2004 2
2005 1
2006 2
2007 1
2008 3
2009 5
2010 3
2011 7
2012 6
2013 2
2014 6
2015 10
2016 11
2017 9
2018 9
2019 4
2020 6
2021 7
2022 10
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
AML treatment in older adults.
Sehgal A, Boyiadzis M. Sehgal A, et al. Among authors: boyiadzis m. Aging (Albany NY). 2015 Sep;7(9):611-2. doi: 10.18632/aging.100816. Aging (Albany NY). 2015. PMID: 26420822 Free PMC article. No abstract available.
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Cai SF, Huang Y, Lance JR, Mao HC, Dunbar AJ, McNulty SN, Druley T, Li Y, Baer MR, Stock W, Kovacsovics T, Blum WG, Schiller GJ, Olin RL, Foran JM, Litzow M, Lin T, Patel P, Foster MC, Boyiadzis M, Collins RH, Chervin J, Shoben A, Vergilio JA, Heerema NA, Rosenberg L, Chen TL, Yocum AO, Druggan F, Marcus S, Stefanos M, Druker BJ, Mims AS, Borate U, Burd A, Byrd JC, Levine RL, Stein EM. Cai SF, et al. Among authors: boyiadzis m. Blood Adv. 2024 Jan 23;8(2):429-440. doi: 10.1182/bloodadvances.2023010563. Blood Adv. 2024. PMID: 37871309 Free PMC article.
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Duong VH, Ruppert AS, Mims AS, Borate U, Stein EM, Baer MR, Stock W, Kovacsovics T, Blum W, Arellano ML, Schiller GJ, Olin RL, Foran JM, Litzow MR, Lin TL, Patel PA, Foster MC, Redner RL, Al-Mansour Z, Cogle CR, Swords RT, Collins RH, Vergilio JA, Heerema NA, Rosenberg L, Yocum AO, Marcus S, Chen T, Druggan F, Stefanos M, Gana TJ, Shoben AB, Druker BJ, Burd A, Byrd JC, Levine RL, Boyiadzis MM. Duong VH, et al. Among authors: boyiadzis mm. Cancer. 2023 Aug 1;129(15):2308-2320. doi: 10.1002/cncr.34780. Epub 2023 Apr 20. Cancer. 2023. PMID: 37078412 Clinical Trial.
Immunotherapy for acute leukemia.
Boyiadzis M, Whiteside TL, Pavletic SZ. Boyiadzis M, et al. Aging (Albany NY). 2015 Jun;7(6):354-5. doi: 10.18632/aging.100768. Aging (Albany NY). 2015. PMID: 26143183 Free PMC article. No abstract available.
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
Saliba AN, Kaufmann SH, Stein EM, Patel PA, Baer MR, Stock W, Deininger M, Blum W, Schiller GJ, Olin RL, Litzow MR, Lin TL, Ball BJ, Boyiadzis MM, Traer E, Odenike O, Arellano ML, Walker A, Duong VH, Kovacsovics T, Collins RH, Shoben AB, Heerema NA, Foster MC, Peterson KL, Schneider PA, Martycz M, Gana TJ, Rosenberg L, Marcus S, Yocum AO, Chen T, Stefanos M, Mims AS, Borate U, Burd A, Druker BJ, Levine RL, Byrd JC, Foran JM. Saliba AN, et al. Among authors: boyiadzis mm. Blood Adv. 2023 Jun 13;7(11):2360-2363. doi: 10.1182/bloodadvances.2022008625. Blood Adv. 2023. PMID: 36315007 Free PMC article. Clinical Trial. No abstract available.
Aging, immunity and cancer.
Hakim FT, Flomerfelt FA, Boyiadzis M, Gress RE. Hakim FT, et al. Among authors: boyiadzis m. Curr Opin Immunol. 2004 Apr;16(2):151-6. doi: 10.1016/j.coi.2004.01.009. Curr Opin Immunol. 2004. PMID: 15023406 Review.
97 results